IN30758 / InxMed - LARVOL DELTA

InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC (PRNewswire) - "InxMed...is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to enhance efficacy and improve safety of ADCs, and IN30758, a First-in-class ADC for treatment of multiple solid tumors including DXD resistant cancers....Preclinical data demonstrated that ifebemtinib was able to reduce the fibrotic barrier, enhance the penetration of ADC, and boost efficacy....IND for Ifebemtinib in combination with ADC will be submitted to China CDE in Nov 2024....Preclinically, IN30758 exhibits robust in vivo efficacy in CDX and PDX models of multiple cancers and well tolerated in cynomolgus monkeys. IN30758 will be ready for IND submission in 2025."

New trial • Preclinical • Solid Tumor